Company Overview
| Stock Name | Peijia-B |
|---|---|
| Stock Code | 09996 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們專注於中國高增長的介入手術醫療器械市場,且為中國各經導管瓣膜治療醫療器械市場及神經介入手術醫療器械市場中具領先地位的國內參與者。 |
| Listing Date | 2020-05-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區中田巷8號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.peijiamedical.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 15.36 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 15,360 |
| Par Value | To be extracted |
| Offer Period | 2020-05-05 to 2020-05-08 |
| Global Offering Shares | 152,511,000 shares |
| HK Public Offer Shares (Initial) | 15,252,000 shares (10.0%) |
| Public Offer Lots (Initial) | 15,252lots (Pool A7,626lots,Pool B7,626lots) |
| International Placing Shares (Initial) | 137,259,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 610,044,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 50.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,342,568,960 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 15,360 |
| 2 lots | 2,000 | HK$ 30,720 |
| 3 lots | 3,000 | HK$ 46,080 |
| 4 lots | 4,000 | HK$ 61,440 |
| 5 lots | 5,000 | HK$ 76,800 |
| 6 lots | 6,000 | HK$ 92,160 |
| 7 lots | 7,000 | HK$ 107,520 |
| 8 lots | 8,000 | HK$ 122,880 |
| 9 lots | 9,000 | HK$ 138,240 |
| 10 lots | 10,000 | HK$ 153,600 |
| 15 lots | 15,000 | HK$ 230,400 |
| 20 lots | 20,000 | HK$ 307,200 |
| 25 lots | 25,000 | HK$ 384,000 |
| 30 lots | 30,000 | HK$ 460,800 |
| 35 lots | 35,000 | HK$ 537,600 |
| 40 lots | 40,000 | HK$ 614,400 |
| 45 lots | 45,000 | HK$ 691,200 |
| 50 lots | 50,000 | HK$ 768,000 |
| 60 lots | 60,000 | HK$ 921,600 |
| 70 lots | 70,000 | HK$ 1,075,200 |
| 80 lots | 80,000 | HK$ 1,228,800 |
| 90 lots | 90,000 | HK$ 1,382,400 |
| 100 lots | 100,000 | HK$ 1,536,000 |
| 200 lots | 200,000 | HK$ 3,072,000 |
| 300 lots | 300,000 | HK$ 4,608,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 400 lots | 400,000 | HK$ 6,144,000 |
| 500 lots | 500,000 | HK$ 7,680,000 |
| 600 lots | 600,000 | HK$ 9,216,000 |
| 700 lots | 700,000 | HK$ 10,752,000 |
| 800 lots | 800,000 | HK$ 12,288,000 |
| 900 lots | 900,000 | HK$ 13,824,000 |
| 1,000 lots | 1,000,000 | HK$ 15,360,000 |
| 1,500 lots | 1,500,000 | HK$ 23,040,000 |
| 2,000 lots | 2,000,000 | HK$ 30,720,000 |
| 2,500 lots | 2,500,000 | HK$ 38,400,000 |
| 3,000 lots | 3,000,000 | HK$ 46,080,000 |
| 3,500 lots | 3,500,000 | HK$ 53,760,000 |
| 4,000 lots | 4,000,000 | HK$ 61,440,000 |
| 4,500 lots | 4,500,000 | HK$ 69,120,000 |
| 5,000 lots | 5,000,000 | HK$ 76,800,000 |
| 6,000 lots | 6,000,000 | HK$ 92,160,000 |
| 7,000 lots | 7,000,000 | HK$ 107,520,000 |
| 7,626 lots | 7,626,000 | HK$ 117,135,360 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 3.38B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +187% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 9,370,275,840 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 142,268,960 |
| Listing Expenses / Funds Raised | ~6.07% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Balance Sheet
| Item | 2018 |
|---|---|
| Cash and cash equivalents | 28,782 |
| Inventories | 5,506 |
| Total current assets | 82,420 |
| Total assets | 136,167 |
| Total current liabilities | 44,287 |
| Total liabilities | 47,530 |
| Total equity | 88,637 |
| Equity attributable to owners | 89,573 |
Cash Flow Statement
| Item | 2018 |
|---|---|
| Net cash from operating activities | -25,089 |
| Net cash from investing activities | -1,361 |
| Net cash from financing activities | 53,558 |
| Net increase in cash | 27,108 |
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 25.8 |
|---|---|
| First Day Open | HK$ 26.8 |
| First Day Change | 67.97% |
| First Day Volume | 93141300.0 |
| First Day Turnover | 2441970000.0 |
| Use of Proceeds | 1、約65.0%(或1,430.2百萬港元),將撥作開發及商業化我們的核心產品TaurusOne?以及其他主要在研產品;
2、約10.0%(或220.0百萬港元),將用于我們管線中的其他在研產品的正在進行的臨床前研究及擬訂的臨床試驗、準備注冊備案及潛在商業化推出;
3、約8.0%(或176.0百萬港元),將用于加強我們的研發能力以豐富我們的產品管線,其主要包括為我們的內部研發團隊招聘及支付三年薪金予高素質人才,尤其是具有豐富設計及開發技能及經驗的工程師;
4、約10.0%(或220.0百萬港元),將用于通過潛在戰略收購、投資、合作伙伴及許可機會以擴大我們的產品組合或知識產權組合;
5、約7.0%(或154.1百萬港元),將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (2)
Overall Coordinators (4)
Joint Bookrunners (6)
Joint Lead Managers (6)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | AIHC Master Fund | 7,741,440 HKD | — | 0.33% | — | 6 months | 2020-11-15 |
| 2 | Cormorant Asset Management, LP | 62,008,320 HKD | — | 2.65% | — | 6 months | 2020-11-15 |
| 3 | Fidelity International | 387,548,160 HKD | — | 16.54% | — | 6 months | 2020-11-15 |
| 4 | Hudson Bay Master Fund LTD | 77,506,560 HKD | — | 3.31% | — | 6 months | 2020-11-15 |
| 5 | LAV Aero Limited | 38,753,280 HKD | — | 1.65% | — | 6 months | 2020-11-15 |
| 6 | Octagon Investments Master Fund LP | 62,008,320 HKD | — | 2.65% | — | 6 months | 2020-11-15 |
| 7 | OrbiMed Funds | 77,506,560 HKD | — | 3.31% | — | 6 months | 2020-11-15 |
| 8 | Prime Capital Funds | 100,761,600 HKD | — | 4.30% | — | 6 months | 2020-11-15 |
| 9 | Rock Springs Capital Master Fund LP | 62,008,320 HKD | — | 2.65% | — | 6 months | 2020-11-15 |
| 10 | Sage Partners Master Fund | 7,741,440 HKD | — | 0.33% | — | 6 months | 2020-11-15 |
| 11 | 常春藤资产管理(香港)有限公司 | 7,741,440 HKD | — | 0.33% | — | 6 months | 2020-11-15 |
| 12 | 铭基基金 | 77,506,560 HKD | — | 3.31% | — | 6 months | 2020-11-15 |
| 13 | 新华资本管理有限公司 | 46,494,720 HKD | — | 1.98% | — | 6 months | 2020-11-15 |
| 14 | 中国国有企业结构调整基金股份有限公司 | 155,013,120 HKD | — | 6.62% | — | 6 months | 2020-11-15 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 張一 | — |
| Company Secretary | 周慶齡 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 張一(張博士)、張葉萍太太、葉紅女士、Jinnius Drive Trust、Hanlindale Trust及XinYue International Limited為一致行動人士,緊隨全球發售完成後合共持有約23.68%投票權;LAV合共持有約10.23%;HH SUM-XXIV Holdings Limited持有約6.84%;Matrix Partners China IV, L.P.及Matrix Partners China IV-A, L.P.合共持有約6.50%;祝進女士持有約5.91%。 |
|---|




